Biopsies from patients with metastatic melanoma treated with anti-PD-1 monotherapy (nivolumab) in part 1 of the CheckMate 038 study showed an increase in immune cell subtypes with elevated immune activation gene signatures seen in responders to therapy [25]. This evidence concerns the gene PDCD1 and metastatic melanoma.